Table 4.

Summary of clinical trials with systemically administered NDV

Viral strain	Route	Type of cancer	Type of study and patient number (n)	Clinical outcome	Ref.
NDV MTH-68	*IV, *IH, *IC	Various advanced	Case series (n=4)	*PR or *CR, with long- term benefit	[143]
NDV MTH-68	*IH	Various advanced	Phase II, n=59, placebo-controlled	Improved OS	[159]
NDV MTH-68	IV	Glioblastoma	Case series (n=14)	7/14 responses, long-term benefit in 4 patients	[163]
NDV PV-701	IV	Various advanced	Phase I, n=79	1 CR, 1 PR, 7 SD	[165]
NDV PV-701	IV	Various advanced	Phase I, n=18	1 CR, 3 PR, 2 SD	[166]
NDV PV-701	IV	Various advanced	Phase I, n=16	Improved tolerability with desensitization	[164]
NDV HUJ	IV	Glioblastoma	Phase I/II, n=14	One transient CR	[167]

^*IV: intravenous,

^*IH: inhalational,

^*IC: intracolonic,

^*PR: partial response,

^*CR: complete response,

^*SD: stable disease